Complix will have access to the Selexis SUREtechnology Platform™ for the production of high-expressing and stable clonal cell lines for use in the development and commercial manufacturing of CMX-02.
This expansion enables Crown Bioscience to diversify its global portfolio of syngeneic models into orthotopic variants, and additional announcements on new models and capabilities at its UK facilities
To acquire biologics manufacturing facility and capabilities from XOMAAcquires rights to Selexis cell line development technology. Purchases an exclusive license to a Phage Display library from Iontas
Working at the forefront of SCLC research, Crown Bioscience developed the HuPrime® and PDXact™ Jumpstart collections of SCLC models, which are the most comprehensive collection of commercially avai...
Using clinically-relevant models, Crown Bioscience helps researchers make the best decisions to speed the optimum drug candidates to clinical development.
With the best-in-class RCB generation capabilities of Selexis on board, the existing knowledge and infrastructure for the manufacturing of therapeutic monoclonal antibodies is optimally leveraged.
20 of 23
Receive JSR Life Sciences news on your RSS reader.
